David M. Mott, Director, 10% Owner at Adaptimmune Therapeutics PLC (ADAP), bought 7,500,000 shares at $0.67 ($5.0M) on 2020-01-24, disclosed to the SEC on 2020-01-28.
Open-market purchase of $5.0M ADAP by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| ARDX | BUY | 2025-06-11 | $738K | — | Filing → |
| ARDX | BUY | 2025-05-19 | $329K | — | Filing → |
| ARDX | BUY | 2025-05-05 | $3.2M | — | Filing → |